Thieler Law Corp advises investors with losses exceeding $100,000 of the August 31, 2015 lead plaintiff deadline in a class action lawsuit filed against Celladon Corporation (NASDAQ: CLDN) (“Celladon” or “the Company”). The suit is pending in the U.S. District Court for the Southern District of California and investors, who Celladon securities between July 7, 2014 and June 25, 2015, have until August 31, 2015 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Celladon securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 866-6157 or emailing mail@thielerlaw.com .  No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose potentially adverse details about Celladon’s  prospects for MYDICAR—the Company’s promising investigational drug for heart failure patients. 

On April 26, 2015, Celladon announced that the Company's Phase 2b CUPID2 trial of MYDICAR did not meet its primary and secondary goals.  The Company reported that "the primary endpoint comparison of MYDICAR to placebo resulted in a hazard ratio of 0.93 (0.53, 1.65 95%CI) (p=0.81), defined as heart failure-related hospitalizations or ambulatory treatment for worsening heart failure" and the "secondary endpoint comparison of MYDICAR to placebo, defined as all-cause death, need for a mechanical circulatory support device, or heart transplant, likewise failed to show a significant treatment effect." 

Following the release of this news, NASDAQ: CLDN shares fell $11.04 per share, closing at $2.64 per share on April 27, 2015. The decline was 80% on volume of 32 million shares.

On June 26, 2015, before the market opened, Celladon announced the suspension of its plans for further research or development of its MYDICAR program and other pre-clinical programs, indicating there was a possibility that the Company could be liquidated with net cash available to shareholders of $25-$30 million. 

After this news was release, NASDAQ: CLDN stock dropped $0.85 per share to close at $1.35 per share on June 26, 2015. The decline was equal to 38% on volume of 9 million shares, and a 95% decline from the stock's Class Period high price.

If you were negatively impacted by your investment in Celladon securities between July 7, 2014 and June 25, 2015, and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185